Operating cash flow was -$35.9M in 2026Q3 against $51.7M of net income, with working capital changes of -$94.2M suggesting receivable or inventory dynamics are a primary driver of persistent cash burn.
Legend Biotech Corporation (LEGN) cash flow statement — 9-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Cash from Operations | -247.8M | -100.47M | -144.03M | -393.28M | -201.28M | -198.47M | -223M | -83.06M | 307.68M | -2.38M |
| Operating CF Margin % | - | -9.76% | -22.96% | -137.92% | -172.03% | -288.36% | -297.34% | -134.41% | 626.22% | -10.07% |
| Operating CF Growth % | -295.88% | 30.25% | 63.38% | -95.39% | -1.42% | 11% | -168.47% | -127% | 13049.58% | - |
| Net Income | -215K | -297.58M | -158.13M | -520.12M | -445.72M | -407.2M | -308.29M | -130.37M | -1.62M | 9.37M |
| Depreciation & Amortization | 50.27M | 28.9M | 23.36M | 20.45M | 18.39M | 13.92M | 9.93M | 5.26M | 1.68M | 217K |
| Stock-Based Compensation | 7.7M | 0 | 68.94M | 47.68M | 34.34M | 20.16M | 4.76M | 1.27M | 704K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -7.35M | -5.66M | 0 |
| Other Non-Cash Items | -1.44M | 261.57M | -98.24M | 130.06M | 10.68M | 12.82M | 93.83M | -4.36M | -6.13M | 228.87M |
| Working Capital Changes | -301.51M | -93.35M | 20.04M | -71.34M | 181.03M | 161.83M | -23.24M | 52.48M | 318.71M | -16.5M |
| Change in Receivables | -125.44M | -132.85M | 93.75M | -98.98M | 50.32M | 24.59M | -45M | -3.77M | 207.61M | -228.06M |
| Change in Inventory | -7.97M | -4.51M | -17.21M | -12.71M | -13.89M | 51K | -643K | -22K | -1.12M | -6K |
| Change in Payables | -26.31M | 44.52M | 14.06M | -50.2M | 72.45M | 1.8M | -4.35M | 2.01M | 3.24M | 4.17M |
| Cash from Investing | 226.82M | 711.48M | -850.54M | 92.79M | -77.09M | -194.98M | -24.17M | -58.65M | -102.26M | -827K |
| Capital Expenditures | -52.49M | -67.58M | -14.11M | -20.08M | -20.93M | -42.2M | -26.25M | -39.17M | -21.02M | -887K |
| CapEx % of Revenue | 3.86% | 6.57% | 2.25% | 7.04% | 17.89% | 61.31% | 35.01% | 63.38% | 42.78% | 3.76% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -460K | 20K | 60K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -135.1M | 0 | -54.34M | -100.52M | -16.05M | -4.91M | -23.52M | 50.52M | -75.23M | 55K |
| Cash from Financing | 115.15M | -300.79K | 5.7M | 791.49M | 377.98M | 626.66M | 618.88M | 14.67M | 2.5M | 3.32M |
| Debt Issued (Net) | -50.6M | 0 | -4.02M | -3.75M | -2.6M | -1.42M | -2.6M | -5.06M | -219K | -32K |
| Equity Issued (Net) | 213.36M | 3.31M | 0 | 0 | 377.64M | 623.44M | 622.53M | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -47.61M | -3.61M | 9.72M | 795.25M | 2.93M | 4.64M | -1.05M | 19.72M | 2.72M | 3.35M |
| Net Change in Cash | 181.76M | 615.09M | -990.96M | 491.68M | 97.09M | 233.25M | 372.32M | -126.8M | 208.05M | 128K |
| Free Cash Flow | -320.88M | -168.04M | -158.14M | -416M | -223.56M | -243.87M | -253.29M | -122.23M | 286.66M | -3.26M |
| FCF Margin % | -23.62% | -16.33% | -25.21% | -145.89% | -191.07% | -354.33% | -337.72% | -197.79% | 583.44% | -13.83% |
| FCF Growth % | -70.06% | -6.26% | 61.99% | -86.08% | 8.33% | 3.72% | -107.21% | -142.64% | 8885.2% | - |
| FCF per Share | -1.66 | -0.91 | -0.86 | -2.36 | -1.41 | -1.73 | -2.14 | -0.93 | 2.86 | -0.02 |
| FCF Conversion (FCF/Net Income) | 1492.45x | 0.34x | 0.81x | 0.76x | 0.45x | 0.49x | 0.84x | 0.82x | -110.52x | -0.25x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LEGN stock.
Legend Biotech Corporation (LEGN) generated $-100.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Legend Biotech Corporation (LEGN) reported negative free cash flow of $168.0M in 2025, indicating capital requirements exceeded cash from operations.
Legend Biotech Corporation (LEGN) spent $67.6M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Persistent operating cash burn
Net Income Unsupported by Operating Cash
Based on reported quarterly figures, LEGN posted $51.7M of net income in 2026Q3 yet generated negative operating cash flow of -$35.9M, an OCF-to-net-income ratio of -0.69 that signals earnings are not converting to cash.
The divergence between accounting profit and operating cash flow suggests the positive quarterly net income is driven by non-cash or partnership-related items rather than collections from patients and partners. Over the last ten quarters, operating cash flow was negative in most periods, which may indicate that reported profitability has limited bearing on the company's actual cash generation. Investors should monitor whether working capital build and milestone timing explain this gap, as the current evidence does not establish a sustainable conversion pathway.
Free Cash Flow Remains Deeply Negative
As reported in financial statements, LEGN's free cash flow margin reached -11.5% in 2026Q3 and was -36.5% in 2026Q1, with cumulative FCF negative across most of the observed ten quarters despite revenue expansion.
Free cash flow has been negative in the majority of recent quarters, with the deepest burn of -$126.6M occurring in 2025Q4 and an intermittent positive print in 2025Q3 that appears to be timing-driven rather than structural. The pattern suggests revenue growth of the Carvykti franchise has not yet translated into self-funding economics. Investors should watch whether FCF margins can move sustainably toward breakeven rather than relying on single-quarter inflections.
Working Capital Swings Dominate Cash Profile
According to reported cash flow statements, working capital changes of -$94.2M in 2026Q3 and -$100.5M in 2026Q2 consumed far more cash than the company's reported depreciation and amortization, indicating receivable or inventory dynamics are a primary cash driver.
The magnitude of working capital outflows relative to D&A suggests collections timing and manufacturing inventory build are material to quarterly cash results. Such swings may reflect milestone receivables or partner settlement timing rather than deteriorating customer demand, though the reported data does not isolate the components. Warrants further investigation into receivable aging and partner reimbursement cadence before drawing firm conclusions about working capital efficiency.
Light Capital Intensity Amid Scaling Needs
Based on reported figures, LEGN's capital expenditure ran at just 1.6% of revenue in 2026Q3 and 8.5% in 2026Q1, a low and volatile intensity that may understate future manufacturing investment requirements.
Capex has been modest relative to revenue, with a peak of $26.0M in 2026Q1, which may reflect reliance on partner-funded or leased manufacturing capacity rather than owned infrastructure. Low capital intensity preserves near-term cash but could mask capacity constraints that require investment as patient volumes scale. Investors should monitor whether capex steps up meaningfully to support additional treatment slots.
Stock Compensation Masks Cash Reality
As reported in financial statements, stock-based compensation was $17.3M in 2026Q2 and $15.0M in 2025Q3, amounts that flatter operating cash metrics relative to a company funding payroll with equity rather than cash.
Stock-based compensation is excluded from operating cash burn in the reported cash flow framework, so the true economic cost of talent retention is higher than the cash figures alone suggest. The absence of dividends and buybacks in the reported periods means the company has no distributions to offset, but also no demonstrated internal funding of growth. Analysts should treat the reported free cash flow as an incomplete picture of economic burn and monitor dilution alongside cash metrics.